Description
InformationTilmicosin (EL 870) is a macrolide antibiotic.In vitroTilmicosin inhibits growth of Pasteurella multocida, Pasteurella haemolytica, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Streptococcus suis, Actinomyces pyogenes and certain other bacteria at levels of 6.25 µg/mL or less. In general, the MICs for Gram-negative enteric bacteria have been greater than 50 µg/mL. Tilmicosin causes decreases in cardiac SOD and GPX activities.In vivoAfter a subcutaneous injection, tilmicosin is eliminated more slowly from serum and milk, with t1/2 beta S of 29.3 and 41.4 hours, respectively. The apparent volume of distribution of tilmicosin is more than 1 L/kg. The peak serum tilmicosin concentration is 1.56 µg/mL. 6.39 hours after a subcutaneous injection of 10 mg/kg. Tilmicosin is extensively secreted into milk, reaching a maximum concentration of 11.6 µg/mL and having a large AUCmilk/AUCserum ratio of approximately 12:1. Tilmicosin is detectable in milk for 11 days after a single subcutaneous dose.Cell Datacell lines：YAPC-PD cells or Panc-1 cellsConcentrations：Incubation Time：Powder Purity:≥99%